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Abstract
The development of cancer has historically been attributed to genomic alterations of normal host cells.
Accordingly, the aim of most traditional cancer therapies has been to destroy the transformed cells themselves.
There is now widespread appreciation that the progressive growth and metastatic spread of cancer cells requires
the cooperation of normal host cells (endothelial cells, fibroblasts, other mesenchymal cells, and immune cells),
both local to, and at sites distant from, the site at which malignant transformation occurs. It is the balance of these
cellular interactions that both determines the natural history of the cancer, and influences its response to therapy.
This active tumor-host dynamic has stimulated interest in the tumor microenvironment as a key target for both
cancer diagnosis and therapy. Recent data has demonstrated both that the presence of CD8+ T cells within a
tumor is associated with a good prognosis, and that the eradication of all malignantly transformed cells within a
tumor requires that the intra-tumoral concentration of cytolytically active CD8+ effector T cells remain above a
critical concentration until every tumor cell has been killed. These findings have stimulated two initiatives in the
field of cancer immunotherapy that focus on the tumor microenvironment. The first is the development of the
immune score as part of the routine diagnostic and prognostic evaluation of human cancers, and the second is
the development of combinatorial immune-based therapies that reduce tumor-associated immune suppression to
unleash pre-existing or therapeutically-induced tumor immunity. In support of these efforts, the Society for the
Immunotherapy of Cancer (SITC) is sponsoring a workshop entitled “Focus on the Target: The Tumor
Microenvironment” to be held October 24-25, 2012 in Bethesda, Maryland. This meeting should support
development of the immune score, and result in a position paper highlighting opportunities for the development
of integrative cancer immunotherapies that sculpt the tumor microenvironment to promote definitive tumor
rejection.
Introduction
Historically, cancer therapies have largely focused on
destroying the transformed cancer cell itself. Local
therapies, including surgery and radiotherapy, aim to
grossly neutralize malignancy, either by removing the
tumor, or by destroying the replicative capacity of the
cancer cells within it. Chemotherapy (and for some can-
cers endocrine therapy) classically exerts an anti-tumor
effect by selectively disrupting an aspect of tumor cell
biology that gives malignant cells a relative growth
advantage compared to normal cells. More recently,
innovative targeted therapies have been developed that
selectively target and disrupt signaling pathways
essential for tumor cell growth; examples include the
HER-2-specific monoclonal antibody Trastuzumab for
breast cancer, and the BRAF inhibitor vemurafenib for
melanoma. Their use results in higher cure rates and
less collateral damage to normal tissues than conven-
tional chemotherapy or radiotherapy. Effectively sequen-
cing these different treatment modalities and using
combinations of drugs with complementary mechanisms
of action and non-overlapping toxicities has reduced the
mortality rates for many cancers [1].
There is now widespread appreciation that non-trans-
formed host cells (endothelial cells, fibroblasts, other
mesenchymal cells, and cells of the innate and adaptive
immune systems) interact with malignant tumor cells to
form a dynamic tumor microenvironment in which the
non-transformed cells exert both positive and negative
effects on the growth and spread of the cancer cells, and
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that these in turn affect the phenotype of the non-trans-
formed host cells [2]. The balance of cellular and secre-
tory-product interactions within this microenvironment
determines whether the tumor mass regresses or grows,
and whether the malignant cells remain in place, or
metastasize to distant sites. In addition, these interac-
tions can determine whether tumors respond well to
radiation or systemic cancer therapy. These interactions
likely also underlie the phenomenon of a mixed clinical
response to therapy, where some metastases regress and
others grow in response to the same treatment [3].
Over the last decade, the influence of host immune
cells both within and surrounding tumors has emerged
as a critical determinant of cancer biology, and a key
factor in the success or failure of human cancer therapy
[4]. Recognition of their impact has produced two major
initiatives in the field of cancer immunotherapy: (1) the
development of the “immune score” as a new and
important component of the routine diagnostic and
prognostic evaluation of human cancers [5], and (2) the
development of combinatorial immune-based therapies
that abrogate tumor-associated immune suppression in
order to unleash the full tumoristatic and tumoricidal
activity of pre-existing or therapeutically-induced immu-
nity [6]. A deeper understanding of how cellular and
molecular interactions within the tumor microenviron-
ment sculpt the activities of innate and antigen-specific
immune cells will lead to integrative cancer immu-
notherapies that selectively impinge on regulatory
mechanisms within the tumor microenvironment to
result in immune-based tumor rejection and clinical
cure. To focus attention on these issues, the Society for
the Immunotherapy of Cancer (SITC) is holding a work-
shop entitled “Focus on the Target: The Tumor Micro-
environment” from October 24-25, 2012 in Bethesda,
Maryland [7].
The interplay of immunity and cancer growth and
progression
The Janus face of the immune system in cancer presents
a complex challenge for tumor immunotherapy. Cells of
the innate and acquired immune systems are involved in
cellular transformation, in the establishment and growth
of tumors, and in the metastasis of malignant tumor
cells. Carcinogenesis results from the inflammation asso-
ciated with a variety of chronic infections [8]. Cells of
the immune system facilitate tumor progression and
spread by selecting for tumor cells intrinsically capable
of escaping immune recognition [4], by creating a tumor
microenvironment that fosters disease progression [4],
and by facilitating the local invasion and subsequent
metastasis of tumor cells [9]. Conversely, cells of the
innate and acquired immune systems can protect
patients against both nascent and established cancers,
either by destroying cancer cells directly, or by establish-
ing and maintaining a state of tumor dormancy [4]. The
influence of the immune system on the natural history
of cancer is further highlighted by observations that the
concentration of CD8+ T cells determines their killing
efficiency in preclinical models [10], and that the quan-
tity, quality, and location of tumor-infiltrating lympho-
cytes (TIL) are predictive of patient survival in cancer
patients [11-14]. For example, in colon cancers, the den-
sity of CD8+ T cells within the tumor predicts patient
survival [11-13]. Furthermore, for many cancers includ-
ing colon cancer, the relative quantity and location of
CD8+ T cells and CD4+CD25+FoxP3+ regulatory T cells
(Treg) are also key predictors of clinical outcome
[12,13]. Genomic profiling of these “good prognosis,”
lymphocyte-infiltrated tumors typically reveals a striking
signature of Th-1-type inflammation that includes mar-
kers of innate immune cell activation, chemokines that
promote T cell trafficking into the tumor parenchyma,
and expression of pro-inflammatory cytokines
[13,15-19]. In parallel, a growing literature illustrates a
role for the immune system in the clinical response to
standard systemic cancer therapy. Individuals with
breast cancer who carry a specific mutation of toll-like
receptor 4 (TLR-4) have a higher risk of relapse after
adjuvant anthracycline-based chemotherapy [20].
Patients with early breast cancers who are treated pre-
operatively with paclitaxel have new immune cell infil-
trates within their tumors at the time of surgery [21].
Similarly, patients treated with Trastuzumab for breast
cancer can develop tumor-specific CD4+ T lymphocytes
within the peripheral blood [22], and within the breast
tumor itself [23].
The immune score
An immune score that quantifies the intra-tumoral loca-
tion and density of CD8+ T cells and memory CD45RO
+ T cells has been proposed as a useful approach both
for predicting the impact of the tumor microenviron-
ment on clinical outcome in colon cancer patients, and
possibly for selecting therapy [13]. The clinical relevance
of the immune score is that the intra-tumoral location
and density of CD8+ T cells and memory CD45RO+ T
cells are tightly correlated with disease-free and overall
survival, and are, in fact, superior to the standard TNM
staging system. Detailed analysis of colon cancer-asso-
ciated lymphocytes reveals that a T helper type 1 profile
is associated with a favorable prognosis, whereas a T
helper type 17 profile is associated with a poor prog-
nosis [24].
Other factors within the tumor microenvironment are
also likely to influence the immune score, including
other immune cells (intra-tumoral Treg, myeloid-derived
suppressor cells, alternatively activated macrophages),
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stromal factors (fibroblasts, other mesenchymal cells,
secretory products like tenascin [25]), and the integrity
of the tumor cell genome. Of these factors, intra-
tumoral Treg are one variable that has been associated
with poor prognosis in many solid tumors (ovarian,
breast, and pancreatic cancers), but paradoxically with
favorable prognosis in colon cancer [26]. Whether can-
cer cell-specific genomic instability, associated with a
more favorable prognosis in ovarian and colorectal can-
cers, is associated with or independent of the immune
score remains to be determined [26,27]. Other elements
of the tumor microenvironment also may shape the
immune score [28]. For example, in lung cancer, low
vascular endothelial growth factor-A (VEGF) and VEGF
Receptor-2 expression in association with high concen-
trations of intra-tumoral CD4+ and CD8+ T cells is
associated with a favorable prognosis [29].
Overall, the association of large numbers of tumor-
associated CD8+, CD45RO+, and granzyme B+ T cells
with improved clinical outcome suggests that these
cells represent the cumulative interactions of diverse
tumor and host-derived cells within the tumor micro-
environment. A major initiative to measure and incor-
porate the numbers of relevant cytotoxic memory CD8
+ T cells (CD8+, CD45RO+, and granzyme B+ T cells)
into standard clinical practice as a tumor immune
score is underway [5]. A concept (based on the task
force meeting “Immunoscoring as a New Possible
Approach for the Classification of Cancer” convened in
Naples, Italy February 13, 2012) will be presented at
the SITC Workshop on the Tumor Microenvironment
in October 2012. This will be followed by a “Workshop
in Immune Scoring” in Naples, Italy in December 2012
that will recommend approaches to the harmonization
of methods for immune scoring of tumors, and seek
acceptance and implementation of immune scoring as
a standard practice in the diagnosis and classification
of cancers.
Re-sculpting the tumor microenvironment to
promote tumor rejection
Given the influence of the tumor microenvironment on
cancer biology and overall clinical outcomes, cancer
therapies that target host elements involved in cancer
development are an increasingly important component
of the standard of care for many cancer types. Agents
that modulate the tumor microenvironment in wide
clinical use today include therapeutic monoclonal anti-
bodies that promote antibody-dependent cellular cyto-
toxicity (Trastuzumab for breast and gastric cancers and
Rituximab for hematologic malignancies), drugs that tar-
get tumor neovascularization (bevacizumab, sunitinib,
and sorafenib for a variety of cancers), and those that
modify the bone microenvironment (the bisphosphonate
zolendronate and the RANKL inhibitor denosumab for
malignant bone disease).
There is increasing evidence that Trastuzumab [22],
Rituximab, and other therapeutic monoclonal antibodies
stimulate clinically relevant adaptive immune responses,
and that they do so in part by cross-priming immune
cells within the locoregional tumor microenvironment
[30,31]. Trastuzumab-like monoclonal antibodies can
promote the evolution of a tumor-specific central mem-
ory CD8+ T cell response in preclinical models [32],
Bevacizumab can alleviate the dendritic cell-based
immune suppression caused by VEGF [33], and suniti-
nib can diminish the suppressive influence of intra-
tumoral myeloid-derived suppressor cells and T regula-
tory cells in both preclinical models [34], and in patients
with renal cell carcinoma [35]. Treating established
tumors with a monoclonal antibody specific for the
VEGF receptor 2 as a single agent can induce tumor-
specific T cell immunity associated with tumor rejection
and protection from a subsequent tumor challenge in an
immune competent preclinical model [36]. The bone-
modifying drug zolendronate can augment the activity
of dendritic cells and NK cells, thereby promoting acti-
vation of gδ and ab T cells [37]. It may also modulate
the tumoristatic and tumoricidal activity of tumor-asso-
ciated macrophages [38].
Importantly, immune-modulating drugs that directly
promote anti-tumor immune responses (the sipuleucel-
T vaccine for prostate cancer and the immune check-
point inhibitor Ipilimumab for melanoma) have become
part of the standard of care. Building on these leads, Ipi-
limumab and Bevacizumab have been combined with
tumor vaccines to explore whether they enhance vaccine
potency [39,40]. Trastuzumab has been combined with
distinct cancer vaccines to capitalize on the direct anti-
tumor activity of the antibody as well as its ability to
modulate tumor immunity by various mechanisms
[41,42]. Delineation of the accessory pathways that con-
trol T cell activation has led to the development of tar-
geted checkpoint inhibitors that can further support
immune priming and T cell activity within the tumor
microenvironment. Novel drugs that specifically target
immune regulatory pathways (including toll-like recep-
tor modulators [43], antibodies specific for the PD-1
pathway [44], the OX-40 pathway [45], and the CD40
pathways [46]) are a growing focus of clinical develop-
ment. The impact of epigenetic therapy on tumor
immunity is also an emerging area of investigation [47].
Conclusions
The findings that the proper concentration of tumor-
antigen specific CD8+ T cells is required to control
tumor growth and eradicate antigen-expressing tumor
cells in preclinical models, and that the relative numbers
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and distribution of CD8+ T cells in human cancers is
associated with disease-free and overall survival define a
target goal and biomarker for clinically effective cancer
immunotherapy. To meet that goal, successful immune-
based therapies will likely ultimately integrate strategies
that induce, recruit, and deliver tumor antigen-specific
effector cells by adoptive cellular therapy or active vacci-
nation with approaches that maximize their antitumor
activity by mitigating active pathways of immune sup-
pression within the tumor microenvironment in a scien-
tifically rational manner. Progress in cancer
immunotherapy will also require better characterization
of the tumor-homing capacities, intratumoral concentra-
tion, lifespan, and functional activity of tumor antigen-
specific effector T cells. The successful clinical develop-
ment of such integrative cancer immunotherapies will
require novel clinical trial designs that incorporate
extensive blood, tissue, and imaging correlates in order
to develop strategies that predict the likelihood of
tumor response to immunotherapy, and evaluate
immune and clinical responses in real time by imaging
or tissue sampling. The overall goal of the 2012 SITC
Workshop “Focus on the Target: The Tumor Microen-
vironment” is to focus on distinct aspects of the host-
tumor interaction, and their implications for tumor
immunotherapy. By systematically applying the best
science to re-shape the host-tumor interaction, we will
develop personalized, integrative cancer immunothera-
pies capable of inducing tumor rejection and effecting
cure.
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